journal article·2021-02-25Open access

Anormal Thermal History Effect on the Structural Dynamics of Probucol Infiltrated into Porous Alumina

Agnieszka Talik, Magdalena Tarnacka, Aldona Minecka, Barbara Hachuła, Joanna Grelska, Karolina Jurkiewicz, Kamil Kaminski, Marian Paluch, Ewa Kaminska

Abstract

High Resolution Image Download MS PowerPoint Slide Herein, broadband dielectric (BDS) and Fourier transform infrared spectroscopy (FTIR), together with differential scanning calorimetry (DSC) and X-ray diffraction (XRD), were applied to study the molecular dynamics, molecular interactions as well as physical stability of an amorphous Active Pharmaceutical Ingredient (API)—probucol (PRO)—infiltrated into anodic aluminum oxide (AAO) membranes of pore size, d ∼ 10–160 nm. Interestingly, the behavior of examined substance strongly depends on the applied thermal protocol. Remarkably, for the first time, we observed that the structural dynamics of the slowly cooled PRO under confinement is significantly enhanced when compared to that of the quenched material. This unusual behavior was interpreted as a result of surface-induced effects (including the formation of well-resolved interfacial H-bonded layer and adsorption–desorption processes near the interface) that are magnified by the extremely high sensitivity to density fluctuation of studied PRO, reflected in the enormous pressure coefficient of the glass transition temperature d T g /d p = 427 K/GPa. In fact, FTIR investigations revealed that PRO tends to self-associate under confinement and forms a strongly bonded interfacial layer, which controls the variation in the structural dynamics of core molecules. Finally, we observed that the tendency to crystallize of confined API is reduced with respect to the bulk, even though the critical size of PRO nuclei ( r c ∼ 3 nm) is significantly lower than the smallest examined pore size. Nevertheless, after few weeks of storage, the investigated substance crystallized in larger pores, while it remained stable in the nanochannels of d = 10 nm. A combination of XRD and DSC measurements indicated that the infiltrated PRO forms two polymorphs, the stable form I (dominating in bulk) and unstable form II (prevailing under confinement). That means that porous matrices might be used to obtain and maintain prolonged stability of unstable polymorphic forms of API.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Microfluidic and Capillary Electrophoresis Applications · Mesoporous Materials and Catalysis · Material Dynamics and Properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Physics, University of Silesia in Katowice, 75 Pulku Piechoty 1, 41-500 Chorzow, Poland

Silesian Center of Education and Interdisciplinary Research, University of Silesia in Katowice, 75 Pulku Piechoty 1A, 41-500 Chorzow, Poland

Department of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, ul. Jagiellonska 4, 41-200 Sosnowiec, Poland

Institute of Chemistry, University of Silesia in Katowice, Szkolna 9, 40-006 Katowice, Poland

Funding

Narodowe Centrum Nauki · Slaski Uniwersytet Medyczny

References (88)

Show source-provided references
1. 10.1016/j.apsb.2015.07.00310.1016/j.apsb.2015.07.003 ↗
2. Hillery A. M. · 201610.1201/9781315382579 ↗
3. 10.3390/molecules2307171910.3390/molecules23071719 ↗
4. 10.1002/jps.2205810.1002/jps.22058 ↗
5. 10.1016/j.addr.2003.10.00710.1016/j.addr.2003.10.007 ↗
6. 10.1016/j.powtec.2014.03.03210.1016/j.powtec.2014.03.032 ↗
7. 10.1007/s12247-019-09424-110.1007/s12247-019-09424-1 ↗
8. 10.3390/pharmaceutics1001001810.3390/pharmaceutics10010018 ↗
9. 10.1039/C8CE00707A10.1039/C8CE00707A ↗
10. 10.1016/S0378-5173(02)00455-610.1016/S0378-5173(02)00455-6 ↗
11. Kawakami K. · 2019
12. 10.1002/jps.1016910.1002/jps.10169 ↗
13. 10.1021/js960189610.1021/js9601896 ↗
14. 10.1016/j.ejpb.2016.11.03110.1016/j.ejpb.2016.11.031 ↗
15. 10.1016/S0169-409X(01)00098-910.1016/S0169-409X(01)00098-9 ↗
16. 10.1021/mp200436q10.1021/mp200436q ↗
17. 10.1021/acs.molpharmaceut.7b0099310.1021/acs.molpharmaceut.7b00993 ↗
18. 10.1021/mp500286b10.1021/mp500286b ↗
19. 10.1021/acs.molpharmaceut.7b0022810.1021/acs.molpharmaceut.7b00228 ↗
20. 10.1016/j.ejps.2019.10509110.1016/j.ejps.2019.105091 ↗
21. 10.1023/A:101216741037610.1023/A:1012167410376 ↗
22. 10.1002/jps.2335810.1002/jps.23358 ↗
23. Khodaverdi K. · Iran J. Basic Med. Sci. · 2012 · 15 · 820
24. 10.1002/jps.2225110.1002/jps.22251 ↗
25. 10.1016/j.ejpb.2012.07.01210.1016/j.ejpb.2012.07.012 ↗
26. 10.1016/j.ejpb.2013.03.01410.1016/j.ejpb.2013.03.014 ↗
27. 10.1016/j.ejpb.2013.03.02610.1016/j.ejpb.2013.03.026 ↗
28. 10.3390/pharmaceutics603041610.3390/pharmaceutics6030416 ↗
29. 10.1021/acs.molpharmaceut.7b0038610.1021/acs.molpharmaceut.7b00386 ↗
30. 10.1021/acs.jpcc.6b0407810.1021/acs.jpcc.6b04078 ↗
31. 10.1021/jp107631m10.1021/jp107631m ↗
32. 10.1021/jp500630m10.1021/jp500630m ↗
33. 10.1021/acs.molpharmaceut.5b0090310.1021/acs.molpharmaceut.5b00903 ↗
34. 10.1021/acs.jpcc.7b1094610.1021/acs.jpcc.7b10946 ↗
35. 10.1021/acs.molpharmaceut.8b0072510.1021/acs.molpharmaceut.8b00725 ↗
36. 10.1021/nl504855z10.1021/nl504855z ↗
37. 10.1021/acs.jpcb.5b0875110.1021/acs.jpcb.5b08751 ↗
38. 10.1021/acs.langmuir.9b0049610.1021/acs.langmuir.9b00496 ↗
39. Defay R. · 1966
40. 10.1063/1.45924010.1063/1.459240 ↗
41. 10.1007/s10853-018-03211-y10.1007/s10853-018-03211-y ↗
42. 10.2174/187406770070101001810.2174/1874067700701010018 ↗
43. 10.1021/acs.cgd.5b0118110.1021/acs.cgd.5b01181 ↗
44. 10.1021/acs.jpcc.5b0139110.1021/acs.jpcc.5b01391 ↗
45. 10.1039/C6CP03923E10.1039/C6CP03923E ↗
46. 10.1021/acs.macromol.8b0268710.1021/acs.macromol.8b02687 ↗
47. 10.1063/1.151466410.1063/1.1514664 ↗
48. 10.1016/j.ejps.2019.10503810.1016/j.ejps.2019.105038 ↗
49. 10.1016/j.molliq.2019.11216910.1016/j.molliq.2019.112169 ↗
50. https://www.inredox.com.
51. 10.1039/c004546b10.1039/c004546b ↗
52. 10.1524/zpch.2012.028710.1524/zpch.2012.0287 ↗
53. 10.1021/acs.macromol.6b0148410.1021/acs.macromol.6b01484 ↗
54. 10.1021/acs.jpcc.8b0752210.1021/acs.jpcc.8b07522 ↗
55. Kremer F. · 201410.1007/978-3-319-06100-9 ↗
56. 10.1021/ma500663810.1021/ma5006638 ↗
57. 10.1021/acs.macromol.6b0123710.1021/acs.macromol.6b01237 ↗
58. 10.1063/1.47526510.1063/1.475265 ↗
59. 10.1103/PhysRevLett.115.26570210.1103/PhysRevLett.115.265702 ↗
60. 10.1103/PhysRevB.61.666710.1103/PhysRevB.61.6667 ↗
61. 10.1103/PhysRevE.54.537710.1103/PhysRevE.54.5377 ↗
62. 10.1021/acs.jpcc.5b1274510.1021/acs.jpcc.5b12745 ↗
63. 10.1021/acs.jpcc.0c0406210.1021/acs.jpcc.0c04062 ↗
64. 10.1103/PhysRevLett.122.17610110.1103/PhysRevLett.122.176101 ↗
65. 10.1016/0032-3861(67)90021-310.1016/0032-3861(67)90021-3 ↗
66. Kremer F. · 200310.1007/978-3-642-56120-7 ↗
67. 10.1103/PhysRevLett.79.207710.1103/PhysRevLett.79.2077 ↗
68. 10.1063/1.326650810.1063/1.3266508 ↗
69. 10.1063/1.493330810.1063/1.4933308 ↗
70. 10.1063/1.508033410.1063/1.5080334 ↗
71. 10.1021/acs.langmuir.0c0119410.1021/acs.langmuir.0c01194 ↗
72. 10.1021/jp511248q10.1021/jp511248q ↗
73. 10.1021/ma047690210.1021/ma0476902 ↗
74. 10.1021/acs.jpclett.5b0153310.1021/acs.jpclett.5b01533 ↗
75. 10.1021/acs.jpcc.8b1255110.1021/acs.jpcc.8b12551 ↗
76. Floudas G. · 201110.1007/978-3-642-04902-6 ↗
77. 10.1063/1.494077610.1063/1.4940776 ↗
78. 10.1063/1.162440110.1063/1.1624401 ↗
79. 10.1021/j100488a00710.1021/j100488a007 ↗
80. 10.1021/acs.jpca.9b0079210.1021/acs.jpca.9b00792 ↗
81. 10.1039/C3CS60234F10.1039/C3CS60234F ↗
82. 10.1007/BF0119573310.1007/BF01195733 ↗
83. 10.1016/j.ijpharm.2016.12.02710.1016/j.ijpharm.2016.12.027 ↗
84. Mullin J. W. · 2001
85. 10.1088/0953-8984/17/15/R0110.1088/0953-8984/17/15/R01 ↗
86. 10.1021/cm960118810.1021/cm9601188 ↗
87. 10.1039/C7CP01864A10.1039/C7CP01864A ↗
88. 10.1039/C5CE01148E10.1039/C5CE01148E ↗